Ventures

Karla Therapeutics is exploring an approach, treating mental disorders by leveraging our immune system. Neurodevelopmental disorders like ADHD and OCD are increasingly prevalent, yet treatment options often have side effects and limited effectiveness. By bridging between the immune system and mental health, Karla aims to revolutionize treatment methods. Their research focuses on a specific protein identified by top-tier immunologists, showing promising results in early experiments for OCD, anxiety, and ADHD.

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.

ArtiFex tackles a solution for coronary and peripheral bypass surgeries. Traditional grafts from the great saphenous vein face issues like rapid degeneration, leading to complications. With millions of bypass surgeries conducted annually and a billion-dollar market for vascular grafts, there's a clear need for improvement. ArtiFex's innovative vascular graft, made of cobalt-chrome and cellulose promotes tissue regeneration, strength, and ensures blood flow without causing clotting or immune reactions.

Sansepsis is a new treatment for sepsis, a serious condition causing many hospital deaths. Developed by Sanquin, a top blood bank in Europe, it uses a special filtering technology called apheresis to remove harmful pathogens from the blood. This innovative approach aims to improve patient outcomes and reduce the high costs associated with treating sepsis, offering hope for better management of this deadly condition.

FlowView Diagnostics addresses the challenge of analyzing complex cell data from blood samples using multiparameter flow cytometry, vital for conditions like leukemia monitoring. They tackle this with an algorithm that quickly processes raw data, detecting Minimal Residual Disease (MRD) more accurately and rapidly than manual methods. In a case study, the algorithm analyzed 8 million cells in 2 minutes, presenting simplified results for quicker interpretation, reducing the risk of false negatives, and enhancing efficiency in leukemia monitoring.

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Timelab addresses the challenge of ambulance delays in the Netherlands by offering a proactive solution through their Emergency Mathematics software. With 7% of ambulance arrivals exceeding the 15-minute target, 35,000 patients annually don't receive timely care, impacting mortality and morbidity rates. Timelab's software predicts future demand and facilitates the proactive relocation of ambulances, aiming to reach 95% of high emergency call locations within 15 minutes, compared to the current 93%.

Amotio addresses the challenge of revision surgeries for hip, knee, and shoulder implants with their innovative approach. Collaborating with expert revision surgeons and guided by NLC, they offer a patented solution for improved implant revision surgery. By developing unique bone cement removal devices and integrating advanced patient-specific 3D surgical planning and printing technology, Amotio aims to set a new standard for excellence in these surgeries. Their goal is to reduce complexity, trauma, and recovery time while cutting costs for healthcare providers.